Loading...

Saturday 27.10.2018

08:45–10:15
Workshop 1 (Parallel Sessions)

Radiotherapy in Salvage

Room:Martin & Augustin (Dorint Hotel)
08:45–10:15
Workshop 2 (Parallel Sessions)

Molecular Pathogenesis

Room:Kleiner Saal
08:45–10:15
Workshop 3 (Parallel Sessions)

Developing Health Care Environments

Room:Marsilius Saal
08:45–10:15
Workshop 4 (Parallel Sessions)

PET

Room:Großer Saal
  • 08:45

    PET / CT – The perspective from the German Hodgkin Study Group

  • 09:15

    PET guided strategy in Hodgkin lymphoma: issues and perspectives

  • 09:45

    Measurement of metabolic volume and threshold in Hodgkin Lymphoma: how to move to a standard

10:30–12:00
Workshop 5 (Parallel Sessions)

Survivorship

Room:Kleiner Saal
  • 10:30

    Genetic determinants of radiation-induced breast cancer after HL

  • 10:45

    Genetic polymorphisms associated with anthracycline-induced cardiotoxicity

  • 11:00

    Genetic determinants for acute radiation toxicity

  • 11:15

    Genetic susceptibility for treatment-related adverse effects: How can we make signi cant progress?

  • 11:30

    Panel Discussion

10:30–12:00
Workshop 6 (Parallel Sessions)

Challenges in older Lymphoma Patients

Room:Marsilius Saal
10:30–12:00
Workshop 7 (Parallel Sessions)

Immunotherapy: Chances & Pitfalls

Room:Großer Saal
  • 10:30

    The role of radiotherapy for Hodgkin Lymphoma in the era of PD-1 blockade

  • 11:00

    Impact of PD-1 blockade on the treatment landscape of Hodgkin Lymphoma

  • 11:30

    Pitfalls in clinical trial design and interpretation with immunotherapy

10:30–12:00
Workshop 8 (Parallel Sessions)

Minimum Residual Disease

Room:Martin & Augustin (Dorint Hotel)
12:15–13:45
Scientific Symposium

Biosimilar rituximab – a new treatment option

Room:Großer Saal
  • 12:15

    Biosimilar Development in Oncology

  • 12:45

    Clinical evidence for biosimilar rituximab

  • 13:15

    Treatment of CD20 positive, lymphocyte-predominant Hodgkin lymphoma

14:00–15:30
Scientific Session 1

Immunotherapy – Biomechanisms

Room:Großer Saal
16:00–17:30
Scientific Symposium

Advanced HL: How Can We Do Better?

Room:Großer Saal
  • 16:00

    Introduction: Brief overview of key milestones in HL management over recent years

  • 16:10

    Can we do better in front-line?

  • 16:30

    iPad Audience Q&A with panel discussion

  • 16:35

    Can we do better with salvage?

  • 16:55

    iPad Audience Q&A with panel discussion

  • 17:00

    Can we do better in assessing risk of failure throughout the patient journey?

  • 17:20

    iPad Audience Q&A with panel discussion

  • 17:25

    Chairman’s wrap-up

17:45–19:15
Main Program

Opening Ceremony

Room:Großer Saal
  • 17:45

    Introduction and Welcome from the Symposium Chairman

  • Welcoming Address

  • Welcoming Address

  • Key Note Lecture: The role of patient advocacy and patient involvement in research

  • Awards Ceremony

19:45
Main Program

Welcome Reception

Room:Weinkeller

Sunday 28.10.2018

07:30–09:00
Scientific Session 2

Interactive Case Discussion

Room:Großer Saal
09:15–10:15
Scientific Symposium

Oncology meets Autoimmunity

Room:Großer Saal
  • 09:15

    Autotransplant in systemic sclerosis

  • 09:45

    Autoimmunity in chronic GVHD

10:30–12:00
Scientific Session 3

Biology & Microenvironment

Room:Großer Saal
12:15–13:45
Scientific Symposium

Tailoring sequencing and treatment targets

Room:Großer Saal
14:00–15:30
Scientific Session 4

Early Stages

Room:Großer Saal
  • 14:00

    Early-Stage Favorable HL: HD16

  • 14:20

    BREACH: Randomized Phase II Trial

  • 14:40

    Abstract Talk: T012 Relapses in early PET-negative stage I/II Hodgkin Lymphoma (HL) after combined modality treatment or chemotherapy only in the EORTC/LYSA/FIL H10 trial

  • 14:50

    Abstract Talk: T013 Maximum tumour dimension at baseline is associated with event-free survival in PET negative patients with stage IA/IIA Hodgkin lymphoma in the UK NCRI RAPID trial

  • 15:00

    Poster Pitch: P027 Cardiovascular Radiation Dosimetry and Predicted Cardiovascular Risks from Involved Field Radiotherapy within the UK ‘RAPID’ Trial in Early Low-Risk Hodgkin Lymphoma

  • 15:05

    Poster Pitch: P029 Quality Assurance of Involved-Node Radiotherapy: First Results of the HD17-Trial of the GHSG

  • 15:10

    Abstract Talk: T014 Multicentric Italian Experience in Treatment of Nodular Lymphocyte Predominant Hodgkin lymphoma (NLPHL) in the Rituximab Era

  • 15:20

    Abstract Talk: T015 Brentuximab Vedotin and AVD Chemotherapy followed by Reduced Dose/Volume Radiotherapy in Patients with Early Stage, Unfavorable Hodgkin Lymphoma

15:30–16:00
Main Program

Poster Session

Room:Kleiner Saal
16:00–17:30
Scientific Symposium

Focus on cHL: Current Insights and Future Perspectives

Room:Großer Saal
17:45–19:15
Scientific Session 5

Survivorship & Patients’ Perspective

Room:Großer Saal
  • 17:45

    What Patients Really Want: The Global Lymphoma Patient Survey

  • 18:05

    Cognitive Behavioral Therapy for Fatigue in HL

  • 18:25

    Genetic Susceptibility

  • 18:45

    Abstract Talk: T016 Employment situation among long-term Hodgkin lymphoma survivors in Europe: An analysis of patients from nine consecutive EORTC-LYSA trials

  • 18:55

    Poster Pitch: P036 Early-Stage Hodgkin Lymphoma (HL) in the Modern Era: Harnessing Simulation Modeling to Delineate Long-Term Patient Outcomes

  • 19:00

    Poster Pitch: P060 The reciprocal relation between cancer-related fatigue and physical and psychosocial functioning in survivors of Hodgkin lymphoma

  • 19:05

    Abstract Talk: T017 Is routine laboratory testing useful in detecting relapse in patients with classic Hodgkin lymphoma in first remission?

  • 19:15

    Abstract Talk: T018 Contemporarily treated Hodgkin lymphoma patients have childbearing potential in line with matched comparators

Monday 29.10.2018

07:30–09:00
Scientific Session 6

Advanced Stages

Room:Großer Saal
  • 07:30

    ECHELON1 Update

  • 07:50

    HD18 Update

  • 08:10

    LYSA AHL2011 Phase III Study

  • 08:30

    Abstract Talk: T019 Potential impact of consolidation radiation therapy for advanced Hodgkin Lymphoma: a secondary modeling analysis of SWOG S0816

  • 08:40

    Abstract Talk: T020 Baseline PET features as predictors of outcome in advanced HL : A prospective evaluation of UK patients in the RATHL trial (CRUK/07/033)

  • 08:50

    Abstract Talk: T021 B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)ne) in older patients with advanced-stage Hodgkin lymphoma: results of a phase II intergroup trial by the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)

09:15–10:15
Scientific Symposium

CAR T Cell Therapies: Hype Or Hope?

Room:Großer Saal
  • 09:15

    Preclinical Rationale for CAR T Cell Therapy

  • 09:35

    CD19 directed CAR T Cell Therapy in B-NHL

  • 09:55

    BCMA directed CAR T Cell Therapy in MM

10:30–12:00
Scientific Session 7

Pediatric HL

Room:Großer Saal
  • 10:30

    PD1/-L1 Expression in Pediatric HL

  • 10:50

    Genotyping in Familial HL

  • 11:10

    Functional and Financial outcomes after Treatment for Pediatric Hodgkin Lymphoma

  • 11:30

    Abstract Talk: T022 Survival by race/ethnicity in pediatric and adolescent patients with Hodgkin lymphoma: A pooled analysis of contemporary Children’s Oncology Group trials

  • 11:40

    Abstract Talk: T023 Safety and early response to the first 2 cycles of Brentuximab Vedotin substituting vincristine in the OEPA / COPDAC regimen for high risk pediatric Hodgkin Lymphoma (HL)

  • 11:50

    Abstract Talk: T024 The feasibility of deep inspiration breath-hold in children: Results of the TEDDI pilot study

12:15–13:45
Scientific Symposium

Checkpointblockade in Lymphomas

Room:Großer Saal
14:00–15:30
Scientific Session 8

Immunotherapy – Clinical

Room:Großer Saal
  • 14:00

    Checkmate 205: Cohort D

  • 14:20

    Toxicities from Checkpoint Inhibitor Therapy: Diagnosis, Management and Follow-up

  • 14:40

    Abstract Talk: T025 Brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma: follow-up results from the phase 1/2 study

  • 14:50

    Abstract Talk: T026 A Phase II study of SHR-1210, an anti-PD-1 antibody, in Chinese Patients with Relapsed/Refractory classic Hodgkin Lymphoma

  • 15:00

    Poster Pitch: P105 A phase II study of Pembrolizumab (PEM) followed by AVD for frontline treatment of classical Hodgkin Lymphoma (cHL): interim results

  • 15:05

    Abstract Talk: T027 Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years

  • 15:15

    Abstract Talk: T028 Allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory classical Hodgkin Lymphoma (cHL) patients treated with Nivolumab is associated with an unprecedented low relapse rate

15:30–16:00
Main Program

Poster Session

Room:Kleiner Saal
16:00–17:30
Scientific Session 9

Relapsed/Refractory HL

Room:Großer Saal
  • 16:00

    Transplant BRaVE : Phase II trial

  • 16:20

    Novel Agents in First Line Salvage

  • 16:40

    Abstract Talk: T029 Second Autologous Stem Cell Transplantation (ASCT) for Relapsed or Refractory (R/R) Hodgkin Lymphoma (HL) after a Previous Autograft: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.

  • 16:50

    Abstract Talk: T030 Bendamustine, Gemcitabine, and Dexamethasone (BGD) Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) Is Effective Treatment for Patients with Relapsed/Refractory Hodgkin Lymphoma (rHL) – Results of the Polish Lymphoma Research Group

  • 17:00

    Poster Pitch: P118 Long Term Safety and Efficacy of Combination of Brentuximab Vedotin and Ipilimumab or Nivolumab in Relapsed / Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412)

  • 17:05

    Poster Pitch: P126 PD-1 blockade for Hodgkin Lymphoma after Allogeneic Stem Cell Transplantation

  • 17:10

    Abstract Talk: T031 Five-Year Progression-Free Survival Outcomes From a Pivotal Phase 3 Study of Consolidative Brentuximab Vedotin After Autologous Stem Cell Transplant in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression (AETHERA).

  • 17:20

    Abstract Talk: T032 Relapse after Early-Stage Favorable Hodgkin Lymphoma: Disease Characteristics, Treatment Strategies and their Outcome

17:30–18:15
Main Program

Closing Remarks

Room:Großer Saal

Basement

Allocations

  • Weinkeller

Wardrobe Stair to Ground Floor Stair to Ground Floor Weinkeller Basement

Ground Floor

Allocations

  • Kleiner Saal

    Workshops, Get Together, Poster Walk

  • Marsilius Saal

    Workshop

Registration Speakers Ready Room PC Pool / Internet Stair to Basement Stair to Basement Stair to First Floor Stair to First Floor Kleiner Saal Marsilius Saal Ground Floor

First Floor

Allocations

  • Großer Saal

    Main Program, Satellite Symposia, Workshop

  • Isabellensaal

    Workshops, Exhibition

Stair to Ground Floor Stair to Ground Floor Großer Saal Isabellensaal First Floor

Dorint Hotel: First Floor

Allocations

  • Martin & Augustin

Martin & Augustin Dorint Hotel: First Floor

Exhibition

Stair to Ground Floor Stair to Ground Floor Großer Saal Isabellensaal

Immunotherapy - Biology and Mechanisms

Selected for Oral Presentation

  • T004 (0051) Expression of PD-1 and PD-L1 increase in multiple consecutive biopsies in patients with classical Hodgkin lymphoma

    • Ingrid Glimelius
    • Rose-Marie Amini
    • Beatrice Ginman
    • Daniel Molin
    • Gunilla Enblad
    • Peter Hollander
  • T005 (0077) Trabectedin inhibits classical Hodgkin Lymphoma growth, monocytes immunosuppressive polarization by tumor cells and synergizes with the CCR5-antagonist Maraviroc

    • Naike Casagrande
    • Cinzia Borghese
    • Elena Mariotto
    • Cristina Vicenzetto
    • Andrea Favero
    • Donatella Aldinucci
    • CB and NC cofirst Authors
  • T006 (0079) The peripheral blood Neutrophil PD-L1 and lymphocyte PD-1 axis in classical Hodgkin lymphoma at diagnosis

    • A.Cuccaro
    • I.Zangrilli
    • F.Corrente
    • E.Cupelli
    • F.Fatone
    • E.Galli
    • E.Maiolo
    • S.Annunziata
    • V.Rufini
    • M.Balducci
    • F.D'Alò
    • S.Bellesi
    • V.De Stefano
    • S.Hohaus
  • T007 (0099) PD-L1+ and IDO-1+ tumor-associated macrophages predict survival in primary classical Hodgkin lymphoma

    • Kristiina Karihtala
    • Suvi-Katri Leivonen
    • Teijo Pellinen
    • Oscar Brück
    • Marja-Liisa Karjalainen-Lindsberg
    • Satu Mustjoki
    • and Sirpa Leppä

Selected for Poster Pitch

  • P002 (0061) Development of an α-CD30 Bispecific Antibody Immunotherapy for Hodgkin Lymphoma

    • Schwartz
    • Cindy L
    • Oldham
    • Robyn AA
    • Faber
    • Mary L
    • Thakur A
    • Lum
    • Lawrence G
    • Medin
    • Jeffrey A

Posters

  • P001 (0015) Hodgkin‘s Variant of Richter Transformation in the Czech Republic

    • Mociková H
    • Sýkorová A
    • Marková J
    • Klásková K
    • Šimkovič M.
    • Smolej L
    • Kalinová M
    • Campr V
    • Kozák T
    • on behalf of the Czech Hodgkin Lymphoma Study Group
  • P003 (0157) Microsatellite and chromosomal instability constitute two mechanisms that independently lead to genomic instability in Hodgkin lymphoma.

    • Radhia M’Kacher
    • Corina Cuceu
    • Bruno Colicchio
    • Steffen Junker
    • François Plassa
    • Justyna Mika
    • Monika Frenzel
    • Mustafa AL Jawhari
    • William M. Hempel
    • Grainne O’Brien
    • Luc Morat
    • Theodore Girinsky
    • Alain Dieterlen
    • Joanna Polanska
    • Christophe Badie
    • Eric Jeandidier
    • Patrice Carde

Biology and Microenvironment

Selected for Oral Presentation

  • T001 (0006) CK2A is overexpressed, active and targetable with silmitasertib In classical Hodgkin Lymphoma

    • Visentin A.
    • Frezzato F.
    • Severin F.
    • Pizzi M.
    • Martini V.
    • Raggi F.
    • Imbergamo S
    • Scomazzon E
    • Pravato S
    • Manni S.
    • Facco M.
    • Carlo-Stella C.
    • Semenzato G.
    • Piazza F.
    • Trentin L.
  • T002 (0076) Low B-cell content at diagnosis is associated with adverse outcome in advanced stage classical Hodgkin Lymphoma

    • Ron D. Jachimowicz
    • Luise Pieper
    • Artur Gontarewicz
    • Annette Plütschow
    • Heinz Haverkamp
    • Sarah Reinke
    • Christoph Thorns
    • Martin Leo Hansmann
    • Peter Möller
    • Andreas Rosenwald
    • Harald Stein
    • Christian Kohler
    • Gunther Glehr
    • H. Christian Reinhardt
    • Peter Borchmann
    • Bastian v. Tresckow
    • Michael Altenbuchinger
    • Rainer Spang
    • Andreas Engert
    • Wolfram Klapper
  • T003 (0171) ROR-1 receptor is a potential therapeutic target in classical Hodgkin Lymphoma

    • Louloudenia Velentza
    • Ioannis Zerdes
    • Amir Hossein Danesh Manesh
    • Nikolaos Tsesmetzis
    • Mohammad Hojat-Farsangi
    • Amineh Ghaderi
    • Elias Drakos
    • Marzia Palma
    • Anders Österborg
    • Håkan Mellstedt
    • George Z. Rassidakis
  • T008 (0050) Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma patients to determine pathogenic mechanisms and monitor therapy

    • Andreas Bräuninger
    • Ann-Kathrin Desch
    • Kristin Kunze
    • Ante Boten
    • Alexander Brobeil
    • Mathias Rummel
    • Lars Kurch
    • Thomas Georgi
    • Regine Kluge
    • Christine Mauz-Körholz
    • Dieter Körholz
    • Stefan Gattenlöhner
  • T009 (0083) Circulating Tumor DNA as a Biomarker for the Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma

    • Michael C. Jin
    • David M Kurtz
    • Mohammad Shahrokh Esfahani
    • Brian J. Sworder
    • Joseph Schroer-Martin
    • Joanne Soo
    • Cynthia Glover
    • Mark Roschewski
    • Wyndham Wilson
    • Ulrich Düehrsen
    • Andreas Hüttmann
    • Davide Rossi
    • Gianluca Gaidano
    • Jason Westin
    • Maximilian Diehn
    • Ranjana Advani
    • Ash A. Alizadeh
  • T010 (0113) Clinical validation of an extracellular vesicle associated miRNA detection assay to monitor therapy response in classical Hodgkin lymphoma patients

    • E.E.E. Drees
    • M.A.J. van Eijndhoven
    • I. Ciocanea-Teodorescu
    • N.J. Groenewegen
    • L.I. Prins
    • X. Tran
    • A. Valles
    • D. Koppers-Lalic
    • E. Aparicio
    • M. Hackenberg
    • D. de Jong
    • J.M. Zijlstra
    • and D.M. Pegtel
  • T011 (0162) Molecular Mechanisms in the Pathogenesis of Composite Lymphomas

    • Anna Lollies
    • Markus Schneider
    • Sylvia Hartmann
    • Stephan Mathas
    • Enrico Tiacci
    • Marc Andree Weniger
    • Patricia Johansson
    • Jan Dürig
    • Ludger Klein-Hitpass
    • Martin-Leo Hansmann and Ralf Küppers

Selected for Poster Pitch

  • P019 (0158) Functional analysis of CD30 in Hodgkin and anaplastic large cell lymphoma cell lines by CRISPR/Cas9-mediated gene knockout

    • Annika L. Weiß
    • Anna Lollies
    • Freya Kretzmer
    • Marc A. Weniger
    • Ralf Küppers
  • P021 (0168) Copy number aberrations in cell-free DNA of Hodgkin lymphoma

    • Lieselot Buedts
    • Thomas Tousseyn
    • Olivier Gheysens
    • Julio Finalet-Ferreiro
    • Luc Dehaspe
    • Gregor Verhoef
    • Sanne Smits
    • Joris Vermeesch
    • Peter Vandenberghe

Posters

  • P004 (0011) Array-based DNA methylome analyses of classical Hodgkin lymphoma

    • Vogt J.
    • Kretzmer H.
    • Ammerpohl O.
    • Vallés Uriate L.
    • Drexler HG.
    • Wagener R.
    • López C.
    • Siebert R.
  • P005 (0036) The role of TCF3 in classical Hodgkin lymphoma

    • Rianne Veenstra
    • Joost Kluiver
    • Lydia Visser
    • Arjan Diepstra and Anke van den Berg
  • P006 (0037) Recurrent exportin 1 mutations in patients with classical Hodgkin Lymphoma

    • Almudena Navarro-Bailón
    • Cristina Jiménez
    • Sara Alonso-Álvarez
    • Alicia Antón
    • María Carmen Chillón
    • Miguel Alcoceba
    • María García-Álvarez
    • Isabel Prieto
    • Alejandro Medina
    • Verónica González-de-la-Calle
    • Marcos González
    • María Eugenia Sarasquete
    • Ramón García-Sanz
  • P007 (0043) TARC immunohistochemistry in the diagnosis of classical Hodgkin lymphoma

    • Carlijn Veldman
    • Stefano Rosati
    • Anke van den Berg
    • Lydia Visser
    • Wouter Plattel
    • and Arjan Diepstra
  • P008 (0053) Whole-slide-image analysis of the tumormicronenvironment in classical Hodgkin Lymphoma

    • Luise Pieper
    • Sarah Reinke
    • Ron Jachimowicz
    • Annette Plütschow
    • Andreas Engert
    • Wolfram Klapper
  • P009 (0069) CD2 is an important adhesion molecule in the initial interaction between Hodgkin Reed-Sternberg cells and rosetting T cells

    • J. Veldman
    • A. van den Berg
    • L. Visser
    • A. Diepstra
  • P010 (0073) A new reliable and highly specific antibody to detect SOCS1 (Silencer of Cytokine Signaling 1).

    • Stephanie E. Weissinger
    • Malena Zahn
    • Kevin Mellert
    • Ralf Marienfeld
    • Gerhard Moldenhauer
    • Peter Möller.
  • P012 (0081) Soluble cytokines in Hodgkin lymphoma patients treated with a GHSG policy: an analysis of the Czech Hodgkin Lymphoma Study Group

    • Vit Prochazka
    • Marie Lukasova
    • Eva Kriegova
    • Alice Sykorova
    • Heidi Mocikova
    • Tomas Papajik
    • David Belada
    • Jana Markova
    • Katerina Klaskova
    • Veronika Hanackova
    • Gabriela Gabcova
    • Zuzana Mikulková
    • and Pavla Stepankova
    • on behalf of the Czech Hodgkin Lymphoma Study Group
  • P013 (0088) Digital image analysis of the microenvironment in classical Hodgkin lymphoma comparing primary tumor and relapse

    • Franziska Jochims¹
    • Sarah Kretschmer¹
    • Ron Jachimowicz²'³
    • Falko Fend⁴
    • German Ott⁵
    • Martin-Leo Hansmann⁶
    • Christoph Thorns⁷
    • Annette Plütschow³
    • Andreas Engert²'³
    • Wolfram Klapper¹
  • P014 (0098) CD47 is expressed on Hodgkin Reed Sternberg cells in Classical Hodgkin lymphoma.

    • Alonso
    • Lopez-Pereira B
    • Corte
    • Alonso-Alvarez S
    • Fernandez-Vega I
    • García-Moro MA
    • Bernal
    • Alonso-Arias R
    • and Colado E
  • P015 (0100) Characterization of T-cell phenotypes with clinical significance in patients with classical Hodgkin lymphoma

    • Kristiina Karihtala
    • Suvi-Katri Leivonen
    • Teijo Pellinen
    • Oscar Brück
    • Marja-Liisa Karjalainen-Lindsberg
    • Satu Mustjoki
    • and Sirpa Leppä
  • P016 (0104) Phenotypic characterization of circulating T and NK cells in Hodgkin lymphoma patients in relation to tumor burden and treatment

    • Tom A. Mulder
    • Kia Heimersson
    • Barbro Näsman-Glaser
    • Lotta Hansson
    • and Marzia Palma
  • P017 (0120) Immunologic Biomarkers of Response and Resistance to Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

    • Joo Y. Song
    • Wing C. Chan
    • Charles Warden
    • Xiwei Wu
    • Dennis D. Weisenburger
    • Robert Chen
    • Alex F. Herrera
  • P018 (0139) GATA3 expression distinguishes Classic Hodgkin lymphoma from Nodular lymphocyte Hodgkin lymphoma

    • Sridhar Epari
    • Vidya R
    • Hasmukh Jain#
    • Bhausaheb Bagal#
    • Siddharth Laskar
    • Manju Sengar#
    • Sumeet Gujral and Tanuja Shet
  • P020 (0164) Extracellular ciruculating DNA in Hodgkins lymphoma patients: biological corellates and prognostic impact

    • Dino Dujmović
    • Sandra Bašić Kinda
    • Ivo Radman
    • Goran Lauc
    • Ivana Ilić
    • Igor Aurer
  • P022 (0170) The Tumor Suppressor SAMHD1 is Downregulated by MYC in Classical Hodgkin Lymphoma

    • Ioanna Xagoraris
    • Theodoros Vassilakopoulos
    • PhD
    • Nikolas Herold
    • Nikolaos Tsesmetzis
    • MSc.
    • Joseph Khoury
    • Elias Drakos
    • and George Rassidakis
  • P031 (0145) Evaluation of CCL17 (TARC) as a diagnostic biomarker for classical Hodgkin lymphoma: interim results from the CANDEL study.

    • Annette Lake
    • Iain J Nixon
    • Paula Beattie
    • Kim Ah-See
    • Dominic Culligan
    • Nicholas Heaney
    • Pam McKay
    • Omar J Hilmi
    • and Ruth F Jarrett

Early Stages

Selected for Oral Presentation

  • T012 (0066) Relapses in early PET-negative stage I/II Hodgkin Lymphoma (HL) after combined modality treatment or chemotherapy only in the EORTC/LYSA/FIL H10 trial

    • Valeria Fiaccadori
    • Anouk Neven
    • Anne-Claire Gac
    • Luigi Rigacci
    • Theo Girinsky
    • Michel Meignan
    • Martin Hutchings
    • Annibale Versari
    • Oumedaly Reman
    • Umberto Ricardi
    • Marc Andre
    • Massimo Federico
    • John Raemaekers
    • Catherine Fortpied
  • T013 (0095) Maximum tumour dimension at baseline is associated with event-free survival in PET negative patients with stage IA/IIA Hodgkin lymphoma in the UK NCRI RAPID trial

    • Tim Illidge
    • Elizabeth Phillips
    • Nicholas Counsell
    • Ruth Pettengell
    • Peter Johnson
    • Dominic Culligan
    • Bilyana Popova
    • Laura Clifton-Hadley
    • Andrew McMillan
    • Peter Hoskin
    • Sally Barrington
    • John Radford
  • T014 (0118) Multicentric Italian Experience in Treatment of Nodular Lymphocyte Predominant Hodgkin lymphoma (NLPHL) in the Rituximab Era

    • Manuel Gotti
    • Roberta Sciarra
    • Alessandro Pulsoni
    • Francesco Merli
    • Chiara Rusconi
    • Barbara Botto
    • Alessandro Re
    • Andrea Rossi
    • Luigi Rigacci
    • Alberto Fabbri
    • Marina Liberati
    • Michele Merli
    • Luca Nassi
    • Carmelo Carlo Stella
    • Maurizio Bonfichi
    • Valentina Zoboli
    • Germana Tartaglia
    • Isabel Alvarez
    • Erika Meli
    • Maura Nicolosi
    • Daniela Dalceggio
    • Silvia Ferrari
    • Benedetta Puccini
    • Emanuele Cencini
    • Viviana Apoll
  • T015 (0124) Brentuximab Vedotin and AVD Chemotherapy followed by Reduced Dose/Volume Radiotherapy in Patients with Early Stage, Unfavorable Hodgkin Lymphoma

    • Joanna C. Yang
    • Anita Kumar
    • Carla Casulo
    • Ranjana Advani
    • Elizabeth Budde
    • Paul M. Barr
    • Connie L. Batlevi
    • Philip Caron
    • Robert Chen
    • Louis S. Constine
    • Amanda Courtien
    • Savita V. Dandapani
    • Pamela Drullinsky
    • Jonathan W. Friedberg
    • Audrey Hamilton
    • Paul A. Hamlin
    • Richard T. Hoppe
    • Steven M. Horwitz
    • Andrew Intlekofer
    • Oscar Lahoud
    • Matthew J. Matasar
    • Alison J. Moskowitz
    • Ariela Noy
    • Maria L. Palomba
    • Carol S. Portlock
    • Heiko Schöder
    • David J. Straus
    • Santosh Vardhana
    • Shreya

Selected for Poster Pitch

  • P027 (0101) Cardiovascular Radiation Dosimetry and Predicted Cardiovascular Risks from Involved Field Radiotherapy within the UK ‘RAPID’ Trial in Early Low-Risk Hodgkin Lymphoma

    • Dr David J. Cutter
    • MD DPhil
    • Dr Johanna Ramroth
    • DPhil
    • Patricia Diez
    • MSc
    • Andy Buckle
    • David Kennedy
    • Bilyana Popova
    • Laura Clifton-Hadley
    • PhD
    • Prof Tim Illidge
    • MD PhD
    • Prof Sarah C. Darby
    • Prof John Radford
  • P029 (0142) Quality Assurance of Involved-Node Radiotherapy: First Results of the HD17-Trial of the GHSG

    • Kriz J
    • Baues C
    • Oertel M
    • Engenhart-Cabillic R
    • Herfarth K
    • Lukas P
    • Marnitz-Schulze S
    • Schmidberger H
    • Vordermark D
    • Haverkamp U
    • Engert A
    • Eich HT

Posters

  • P023 (0003) Conventional vs multifractionation at radiotherapy for above diaphragm stage II Hodgkin Lymphoma: 30-year experience of single Center

    • Ilyin N. V.
    • Vinogradova J. N.
    • Ivanova E. I.
  • P024 (0009) Limited-Stage Hodgkin Lymphoma: Minimizing Toxicity

    • David J. Straus
    • M.D.
  • P025 (0033) Metabolic tumor volume by positron emission tomography ⁄ computed tomography for deciding the therapeutic modality in patients with early stage Hodgkin’s lymphoma

    • Joo-Seop Chung
    • Moo-Gon Song
    • Do-Young Kim
    • Ho-Jin Shin
    • Seong-Jang Kim
    • Young-Don Joo
  • P026 (0057) Interim- PET Results for Prognosis in Adults with Hodgkin Lymphoma: A Prognostic Factor Exemplar Review (Preliminary Results)

    • Angela Aldin
    • Marialena Trivella
    • Lise J Estcourt
    • Gary Collins
    • Karel Moons
    • Andreas Engert
    • Bastian von Tresckow
    • Carsten Kobe
    • Farid Foroutan
    • Nina Kreuzberger
    • Nicole Skoetz
  • P028 (0102) Patterns of Relapse in Patients Treated for Early Stage Classical Hodgkin Lymphoma in the Modern Era

    • Karin Nielsen MD
    • Maja V. Maraldo MD
    • PhD
    • Anne Kiil Berthelsen MD
    • Annika Loft MD
    • Peter Meidahl Petersen MD
    • Marianne C. Aznar
    • Ivan Richter Vogelius
    • DMSc
    • Peter Brown
    • Lena Specht MD
  • P030 (0143) Once-a-cycle vs. daily G-CSF in early-unfavorable stages of Hodgkin Lymphoma treated with BEACOPP escalated followed by ABVD

    • Michael Fuchs
    • Horst Müller
    • Dennis A. Eichenauer
    • Stefanie Kreissl
    • Andreas Engert
    • and Peter Borchmann
  • P050 (0075) Clinical Characteristics and Prognosis Analysis of Early-Stage Classical Hodgkin Lymphoma

    • Jun Zhu M.D. PhD.
    • Yan-fei Liu M.D.
    • Meng Wu M.D.
    • Mingzi Yang M.D.
    • Aliya M.D.
    • Reyizha Rnuersulitan M.D.
    • Yuqin Song M.D.

Survivorship and Patients Perspective

Selected for Oral Presentation

  • T016 (0018) Employment situation among long-term Hodgkin lymphoma survivors in Europe: An analysis of patients from nine consecutive EORTC-LYSA trials

    • Maja V. Maraldo
    • Michal Kicinski
    • Marleen A.E. van der Kaaij
    • Francesco Giusti
    • Paul Meijnders
    • Berthe M.P. Aleman
    • John M.M. Raemaekers
    • Elisabeth C. Moser
    • Hanneke C. Kluin-Nelemans
    • Michele Spina
    • Christophe Fermé
    • Pauline Brice
    • Olivier Casasnovas
    • Aspasia Stamatoullas
    • Marc André
    • Fabien Le Bras
    • Catherine Fortpied
    • Jan Bogaerts
    • Michel Henry-Amar
    • & Lifang Liu
  • T017 (0044) Is routine laboratory testing useful in detecting relapse in patients with classic Hodgkin lymphoma in first remission?

    • Lynch RC
    • Sundaram V
    • Desai M
    • Henry S
    • Wood D
    • Daadi SE
    • Corbelli K
    • Rosenberg SA
    • Hoppe RT
    • Advani RH
  • T018 (0140) Contemporarily treated Hodgkin lymphoma patients have childbearing potential in line with matched comparators

    • Caroline E. Weibull
    • Anna L.V. Johansson
    • Sandra Eloranta
    • Karin E. Smedby
    • Magnus Björkholm
    • Paul C. Lambert
    • Paul W. Dickman
    • Ingrid Glimelius

Selected for Poster Pitch

  • P036 (0023) Early-Stage Hodgkin Lymphoma (HL) in the Modern Era: Harnessing Simulation Modeling to Delineate Long-Term Patient Outcomes

    • Susan K. Parsons
    • Michael J. Kelly
    • Joshua T. Cohen
    • Sharon M. Castellino
    • Tara O. Henderson
    • Kara M. Kelly
    • Frank G. Keller
    • Tobi J. Henzer
    • Anita J. Kumar
    • Peter Johnson
    • Ralph M. Meyer
    • John Radford
    • John Raemaekers
    • David C. Hodgson
    • Andrew M. Evens
  • P060 (0122) The reciprocal relation between cancer-related fatigue and physical and psychosocial functioning in survivors of Hodgkin lymphoma

    • A. Mayer
    • N. Stadtbäumer
    • S. Kreissl
    • H. Müller
    • H. Görgen
    • P. Borchmann

Posters

  • P032 (0002) Audit of lymphoma patient group irradiated blood product policy compliance at a UK comprehensive cancer centre

    • Jane Gibson
    • Sarah Wells
    • Sharon Jackson
    • Philip Higham
    • Deborah Seal
    • Kim Linton
  • P033 (0007) SINGLE CENTER ANALYSIS OF NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA: FOCUS ON R-ABVD AND INTERIM PET

    • Visentin A
    • Pravato S
    • Scomazzon E
    • Imbergamo S
    • Branca A
    • Gregianin M
    • Vio S
    • Boso C
    • Piazza F
    • Vianello F
    • Zambello R
    • Semenzato G
    • Trentin L
  • P034 (0021) Returning to school or work after Hodgkin lymphoma: An EORTC-LYSA cross-sectional study

    • Maja V. Maraldo
    • Michal Kicinski
    • Marleen A.E. van der Kaaij
    • Francesco Giusti
    • Paul Meijnders
    • Berthe M.P. Aleman
    • John M.M. Raemaekers
    • Elisabeth C. Moser
    • Hanneke C. Kluin-Nelemans
    • Michele Spina
    • Christophe Fermé
    • Pauline Brice
    • Olivier Casasnovas
    • Aspasia Stamatoullas
    • Marc André
    • Fabien Le Bras
    • Catherine Fortpied
    • Jan Bogaerts
    • Michel Henry-Amar
    • & Lifang Liu
  • P035 (0022) Fatigue impairment in Hodgkin and non-Hodgkin lymphoma survivors: A joint EORTC-LYSA cross-sectional survey

    • Nicolas Mounier
    • Raphaël Busson
    • Marleen van der Kaaij
    • Catherine Thieblemont
    • Berthe Aleman
    • Aspasia Stamatoullas
    • John Raemaekers
    • Vincent Ribrag
    • Michele Spina
    • Hervé Tilly
    • Christophe Fermé
    • Corinne Haioun
    • René-Olivier Casasnovas
    • Hanneke Kluin-Nelemans
    • Michel Henry-Amar
  • P037 (0027) The pathway to diagnosis of Hodgkin Lymphoma in South Africa: the determinants and impact of diagnostic delay

    • Antel K
    • Levetan C
    • Mohamed Z
    • Louw VJ
    • Oosthuizen J
    • Verburgh E
  • P038 (0029) Hepatitis B virus infection is not associated with poor prognosis in Hodgkin lymphoma patients: A case-control study

    • Weiping Liu
    • Mingzi Yang
    • Meng Wu
    • Lingyan Ping
    • Yuqin Song
    • Jun Zhu
  • P039 (0030) Temporal trends in treatment-related incidence of diseases of the circulatory system among Hodgkin lymphoma patients

    • Caroline E. Weibull
    • Magnus Björkholm
    • Ingrid Glimelius
    • Paul C. Lambert
    • Therese M. L. Andersson
    • Karin E. Smedby
    • Paul W. Dickman
    • Sandra Eloranta
  • P040 (0031) Clinicopathological features and prognosis of 387 cases with classical Hodgkin lymphoma from China

    • Jun Zhu
    • Mingzi Yang
    • Meng Wu
    • Lingyan Ping
    • Aliya
    • Yanfei Liu
    • Reyizha Nuersulitan
    • Yuqin Song
  • P041 (0034) A study of patient and general practitioner (GP) views and experience of managed local follow-up of long term lymphoma survivors (ADAPT)

    • Sally Taylor
    • Valerie Goode
    • Ellie White
    • Richard Cowan
    • Janelle Yorke
    • John Radford
  • P042 (0035) Anemia has a negative impact on the outcome of patients with Hodgkin lymphoma

    • Weiping Liu
    • Mingzi Yang
    • Meng Wu
    • Lingyan Ping
    • Xiaopei Wang
    • Yuqin Song
    • Jun Zhu
  • P043 (0039) Clinical characteristics and prognostic factors of primary extranodal classical Hodgkin lymphoma: A retrospective study of 27 cases

    • Jun Zhu
    • Mingzi Yang
    • Meng Wu
    • Lingyan Ping
    • Aliya
    • Yanfei Liu
    • Reyizha Nuersulitan
    • Yuqin Song
  • P044 (0046) Investigation the role of adding a serum biomarker to interim PET/CT in Hodgkin lymphoma patients

    • Ádám Jóna
    • Kata Husi
    • Béla Nagy
    • Zsolt Fejes
    • Zsófia Miltényi
    • Árpád Illés
  • P045 (0047) Hyperlipoproteinemia and markers of atherosclerosis progression in long-term survivors of Hodgkin lymphoma in childhood or adolescence and in healthy controls

    • Cepelova M.
    • Kruseova J.
    • Luks A.
    • Cepela P.
    • Potockova J.
    • Kraml P.
  • P046 (0052) No clinical signals of Drug – Drug interaction of NEPA (netupitant + palonosetron) in cHL patients receiving ABVD regimen: a single-center real life experience

    • Vittorio Ruggero Zilioli
    • Periana Minga
    • Lara Crucitti
    • Erika Meli
    • Chiara Rusconi
    • Roberto Cairoli
  • P047 (0058) An Epidemiological Study of Hodgkins Lymphoma from a single tertiary care centre in India with study of disease outcome

    • Dr. Ankita Sen
    • Dr. T.K. Dolai
    • Dr. S.N. Baul
    • Dr. P.K. Mandal
    • Dr. R. De
    • Dr. S. Dutta
    • Dr. P. Chakrabarti
  • P048 (0065) Mature oocytes cryopreservation: a feasible fertility preservation technique in adult Hodgkin lymphoma female patients.

    • Viviani S
    • Somigliana E
    • Filippi F
    • Landi F
    • Paffoni A
    • Mangili G
    • Mazza R
    • Papaleo E
    • Sigismondi C
    • Devizzi L
    • Dodero A
    • Farina L
    • Corradini P
  • P049 (0072) Results of cardiovascular screening in the BETER survivorship care initiative for Hodgkin lymphoma

    • S.R. Pereboom
    • A. Nijdam
    • B.M.P. Aleman
    • R.W.M. van der Maazen
    • J.M. Zijlstra
    • R.J. de Weijer
    • M.B. van ’t Veer
    • J.M.M. Raemaekers
    • F.E. van Leeuwen
    • on behalf of the BETER consortium
  • P051 (0080) Cardiovascular disease risk after treatment-induced premature ovarian insufficiency in female survivors of Hodgkin lymphoma

    • Berthe M.P. Aleman
    • PhD
    • Inge M. Krul
    • MSc
    • Annemieke W.J. Opstal – van Winden
    • Cécile P.M. Janus
    • Laurien A. Daniëls
    • Y. Appelman
    • Angela H.E.M. Maas
    • Frederika A. van Nimwegen
    • Simone de Vries
    • Michael Hauptmann
    • Katarzyna Jóźwiak
    • and Flora E. van Leeuwen
  • P052 (0082) Combined prognostic role of biomarkers and PET/CT in patients with Hodgkin lymphoma

    • Kata Husi
    • Árpád Illés
    • Béla Nagy
    • Zsolt Fejes
    • Judit Bedekovics
    • Zsófia Miltényi
  • P053 (0091) NEUTROPHIL TO LYMPHOCITE RATIO PREDICTS OVERALL SURVIVAL IN NEWLY DIAGNOSED HODGKIN LYMPHOMA PATIENTS - SINGLE CENTRE EXPERIENCE

    • Jelena Hajder
    • Natasa Stanisavljević
    • Dragomir Marisavljević
    • Vladimir Jurišić
    • Olivera Marković
    • Radmila Zivković
  • P054 (0092) Pregnancy in patients in complete remission after Hodgkin Lymphoma: clinical features and outcome.

    • Francesco Gaudio
    • Claudia Nardelli
    • Tommasina Perrone
    • Filomena Emanuela Laddaga
    • Giorgina Specchia
  • P055 (0096) Health-Related Quality of Life (HRQL) Trajectories during Treatment for Advanced Stage Pediatric Hodgkin Lymphoma (HL)

    • Angie Mae Rodday
    • PhD
    • Susan K Parsons
    • MRP
    • Rizvan Bush
    • Qinglin Pei
    • Rachael Curtis
    • Frank Keller
    • Kara Kelly
    • Tara Henderson
    • MPH
    • Sharon M Castellino
    • MSc
  • P056 (0097) Cognitive Dysfunction after Treatment for Hodgkin lymphoma

    • Ferenc Magyari
    • Tibor Ivánka
    • Anikó Égerházi
    • Zsófia Simon
    • Zsófia Miltényi
    • Karolina Kósa
    • Árpád Illés
  • P057 (0108) Cognitive impairments in patients with Hodgkin’s Lymphoma

    • Vinokurova E.G.
    • Marchenko A.A.
    • Khrushchev S.O.
    • Olexenko L.V.
    • Rupchev G.E.
    • Vybornykh D.E.
    • Moiseeva T.N.
  • P058 (0109) Fertility in Hodgkin´s lymphoma patients after initial therapy at Santa Casa de São Paulo Medical School

    • Maria Fernanda Evangelista Simões
    • Gilnara Fontinelle Silva
    • Thaís Rodrigues da Cunha Fischer
    • Carlos Sérgio Chiattone
    • Sergio Costa Fortier
    • Talita Máira Bueno da Silveira da Rocha
  • P059 (0114) AA Amyloidosis Causing Nephrotic Syndrome in Two Patients with Hodgkin Lymphoma

    • Ayse Salihoglu
    • Tugrul Elverdi
    • Dilek Keskin
    • Ahmet Emre Eskazan
    • Muhlis Cem Ar
    • Seniz Ongoren
    • Nukhet Tuzuner
    • Teoman Soysal
    • Zafer Baslar
  • P061 (0125) Chemotherapy-induced polyneuropathy in patients with Hodgkin lymphoma treated with vinca-alkaloids

    • Smardova L
    • Vlckova E
    • Rajdova A
    • Raputova J
    • Bednarik J
    • Kral Z
  • P062 (0134) Long term health care use in relapsed and non-relapsed paediatric and young adult Hodgkin lymphoma patients – a population-based cohort study from Sweden and Denmark

    • Ingrid Glimelius
    • Annika Englund
    • Klaus Rostgaard
    • Karin E. Smedby
    • Sandra Eloranta
    • Peter de Nully Brown
    • Christoffer Johansen
    • Peter Kamper
    • Gustaf Ljungman
    • Lisa Lyngsie Hjalgrim
    • Henrik Hjalgrim
  • P063 (0144) Cognitive impairment, structural and functional brain morphological sequelae of Hodgkin lymphoma treatment. First interim results of ongoing translational study.

    • Tomas Kozak
    • Jiri Horacek
    • Heidi Mocikova
    • Lubica Gaherova
    • Dan Fayette
    • Lucie Geislerova
    • Ivana Karlova
    • Jana Markova
  • P064 (0146) Cause-specific mortality among Hodgkin lymphoma survivors up to 35 years after treatment

    • Simone de Vries
    • Michael Schaapveld
    • Pieternella J. Lugtenburg
    • Laurien A. Daniëls
    • Eefke J. Petersen
    • Josée M. Zijlstra
    • Gustaaf W. van Imhoff
    • Richard W.M. van der Maazen
    • Max Beijert
    • Anna M. van Eggermond
    • Leontien C.M. Kremer
    • Marieke W.J. Louwman
    • Marnix Lybeert
    • Jan Paul de Boer
    • Berthe M.P. Aleman
    • Flora E. van Leeuwen
  • P065 (0150) Elevated neutrophil-to-monocyte ratio is associated with decreased overall survival at 5 years in classic Hodgkin lymphoma

    • D. Neves
    • A. Roque
    • C. Afonso
    • A. Pinto
    • D. Mota
    • R. Guilherme
    • M. Gomes
    • L. Ribeiro
  • P066 (0154) eBEACOPP FOR FRONT-LINE TREATMENT OF PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA (cHL) IN THE REAL WORLD SETTING

    • Sandra Basic-Kinda
    • Dino Dujmovic
    • Ivo Radman
    • Martina Moric Peric
    • Ida Hude
    • Nadira Durakovic
    • Marijo Vodanovic
    • Margareta Dobrenic
    • Marko Kralik
    • Lea Galunic-Bilic
    • Snjezana Dotlic
    • Igor Aurer

Advanced Stages

Selected for Oral Presentation

  • T019 (0026) Potential impact of consolidation radiation therapy for advanced Hodgkin Lymphoma: a secondary modeling analysis of SWOG S0816

    • Chul S. Ha
    • Hongli Li
    • Heiko Schoder
    • Chelsea Pinnix
    • Elizabeth Brem
    • Nancy Bartlett
    • Andrew Evens
    • Eric Hsi
    • Lisa Rimsza
    • John P. Leonard
    • Brad S. Kahl
    • Michael LeBlanc
    • Sonali Smith
    • Louis Constine
    • Jonathan W. Friedberg
  • T020 (0067) Baseline PET features as predictors of outcome in advanced HL : A prospective evaluation of UK patients in the RATHL trial (CRUK/07/033)

    • C Guezennec
    • AA Kirkwood
    • LC Pike
    • P Patrick
    • C Burton
    • F Miall
    • L Stevens
    • L Clifton-Hadley
    • J Radford
    • PW Johnson
    • SF Barrington
  • T021 (0147) B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)ne) in older patients with advanced-stage Hodgkin lymphoma: results of a phase II intergroup trial by the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)

    • Alexander Fosså
    • Boris Böll
    • Helen Goergen
    • Peter Kamper
    • Sirpa Leppä
    • Daniel Molin
    • Julia Meissner
    • Ellen Ritter
    • Jacob Haaber
    • Martin Hutchings
    • Michael Fuchs
    • Andreas Engert
    • Carsten Kobe
    • and Peter Borchmann
    • on behalf of the German Hodgkin Study Group and the Nordic Lymphoma Group

Posters

  • P068 (0008) JUNB, DUSP2, SGK1, CREBBP and SOCS1 are frequently mutated in T-cell/histiocyte rich large B-cell lymphoma

    • Bianca Schuhmacher
    • Julia Bein
    • Tobias Rausch
    • Vladimir Benes
    • Thomas Tousseyn
    • Martine Vornanen
    • Maurilio Ponzoni
    • Randy Gascoyne
    • Christian Steidl
    • Ralf Küppers
    • Martin-Leo Hansmann
    • Sylvia Hartmann
  • P069 (0013) EVALUATION OF CLINICAL CHARACTERISTICS IN PATIENTS WITH INTERIM-PET NEGATIVE BUT POSITIVE END OF TREATMENT PET. DATA FROM THE PROSPECTIVE HD08-01 FIL STUDY.

    • Rigacci L
    • Puccini B
    • Broccoli A
    • Evangelista A
    • Gioia D
    • Dona M
    • Kovalchuk S
    • Santoro A
    • Bonfichi M
    • Re A
    • Pagani C
    • Mannelli L
    • Zaja F
    • Vitolo U
    • Spina M
    • Pulsoni A
    • Nassi L
    • Stelitano C
    • Salvi F
    • Rusconi C
    • Tani M
    • Freilone R
    • Borsatti E
    • Zinzani PL.
  • P070 (0016) HIV-Associated Hodgkin Lymphoma at Groote Schuur Hospital, Cape Town, South Africa

    • Asso/Prof Jessica Opie Dr Luhan Swart Prof Nicolas Novitzky
  • P071 (0024) A Multicenter Phase 2 Study of Sequential Brentuximab Vedotin and AVD Chemotherapy for Older Patients with Untreated Classical Hodgkin Lymphoma

    • Andrew M. Evens
    • Ranjana H. Advani
    • Irene Helenowski
    • PhD
    • Michelle Fanale
    • Sonali M. Smith
    • Borko Jovanovic
    • Gregory R. Bociek
    • Andreas K. Klein
    • Jane N. Winter
    • Leo I. Gordon
    • and Paul A. Hamlin
  • P072 (0038) FRONTLINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY EXHIBITS SUPERIOR MODIFIED PROGRESSION-FREE SURVIVAL VS CHEMOTHERAPY ALONE IN PATIENTS WITH STAGE III OR IV HODGKIN LYMPHOMA: PHASE 3 ECHELON-1 STUDY

    • J. Radford
    • A. Gallamini
    • W. Jurczak
    • D.J. Straus
    • S.M. Ansell
    • W.S. Kim
    • A. Younes
    • S. Alekseev
    • Á. Illés
    • M. Picardi
    • E. Lech-Maranda
    • Y. Oki
    • T. Feldman
    • P. Smolewski
    • K.J. Savage
    • N.L. Bartlett
    • J. Walewski
    • R. Chen
    • R. Ramchandren
    • P.L. Zinzani
    • D. Cunningham
    • D.S. Heo
    • A. Rosta
    • N.C. Josephson
    • E. Song
    • J. Sachs
    • R. Liu
    • H. Jolin
    • D. Huebner
    • J.M. Connors
  • P073 (0045) BEACOPP escalated increases progression free survival in advanced classic Hodgkin lymphoma - a single centre real life experience

    • A. Roque
    • C. Afonso
    • D. Neves
    • A. Pinto
    • D. Mota
    • R. Guilherme
    • M. Gomes
    • L. Ribeiro
  • P074 (0049) Accuracy of PET-based bone marrow assessment in patients with Hodgkin lymphoma: Results from the German Hodgkin Study Group trials HD16, HD17, and HD18

    • Conrad-Amadeus Voltin
    • Helen Goergen
    • Christian Baues
    • Michael Fuchs
    • Jasmin Mettler
    • Stefanie Kreissl
    • Jennifer Oertl
    • Bernd Klaeser
    • Alden Moccia
    • Alexander Drzezga
    • Andreas Engert
    • Peter Borchmann
    • Markus Dietlein
    • Carsten Kobe
  • P075 (0055) Should a bulky mediastinal mass larger than 7cm be considered an adverse prognostic factor in patients with advanced Hodgkin lymphoma and negative interim PET/CT?

    • Rebeca Lopez-Alonso
    • Tania Mashiach
    • Elinor Barzilai
    • Michal Weiler-Sagie
    • Eldad J Dann
  • P076 (0056) Clinical characteristics and treatment outcome of Nodular Lymphocyte Predominant Hodgkin's lymphoma with THRLBCL-like patterns.

    • Dorokhina E.I.
    • Moiseeva T.N.
    • Kovrigina A.M.
    • Shupletsova I.A.
    • Al-Radi L.S.
    • Mangasarova Ya. K.
    • Goryacheva S.R.
  • P077 (0060) Comparison immunoarchitectural patterns of primary, extranodal and bone marrow lesions in nodular lymphocyte predominant Hodgkin lymphoma.

    • Shupletsova I.
    • Kovrigina A.
    • Moiseeva T.
    • Dorokhina E.
  • P078 (0062) Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease

    • Shunan Qi
    • Sarah Milgrom
    • Bouthaina Dabaja
    • Richard Tsang
    • Mario Levis
    • Umberto Ricardi
    • Eldad J Dann
    • Rebecca Lopez-Alonso
    • Andrea Ng
    • Joachim Yahalom
  • P079 (0070) German evidence-based guideline update on diagnosis, therapy and follow-up of adult Hodgkin lymphoma patients

    • T. Jakob
    • M. Follmann
    • P. Borchmann
    • C. Baues
    • S. Sasse
    • P.J. Bröckelmann
    • S. Kreissl
    • D.A. Eichenauer
    • B. von Tresckow
    • C. Bürkle
    • A. Engert
    • N. Skoetz
  • P080 (0071) Analysis of outcomes and prognostic factors of 165 newly diagnosed patients with advanced classical Hodgkin lymphoma

    • Jun Zhu
    • Aliya
    • MengWu
    • Mingzi Yang
    • Yanfei Liu
    • Reyizha Nuersulitan
    • Yuqin Song
  • P081 (0084) A Clinicopathologic Consensus Study of Gray Zone Lymphoma (GZL) with Features Intermediate Between Diffuse Large B-cell Lymphoma (DLBCL) and Classical HL (cHL)

    • Monika Pilichowska
    • Stefania Pittaluga
    • PhD
    • Judith A Ferry
    • Jessica Hemminger
    • Hong Chang
    • Jennifer A. Kanakry
    • Laurie H. Sehn
    • Tatyana Feldman
    • Jeremy S. Abramson
    • Athena Kritharis
    • Francisco J. Hernandez-Ilizaliturri
    • Izidore S. Lossos
    • Oliver W. Press
    • Timothy S. Fenske
    • Jonathan W. Friedberg
    • Julie M. Vose
    • MBA
    • Kristie A. Blum
    • Deepa Jagadeesh
    • Bruce
  • P082 (0087) Clinical significance of autoimmune hemolytic anaemia and autoimmune thrombocytopenia during the course of Hodgkin lymphoma

    • László Pinczés
    • Zsófia Miltényi
    • Ádám Jóna
    • Árpád Illés
  • P083 (0093) Low-dose consolidative mediastinal irradiation in accelerated hyperfractionated regimen for advanced Hodgkin lymphoma

    • Bogatyreva T.I.
    • Pavlov V.V.
    • Terekhova A.Yu.
    • Shklyaev S.S.
    • Falaleeva N.A.
  • P084 (0094) Brentuximab-Vedotin and Bendamustine as first-line treatment of Hodgkin lymphoma in the elderly (HALO trial).

    • GALLAMINI A
    • SCHIANO DE COLELLA JM
    • VIOTTI J
    • BIJOU F
    • RAMBALDI A
    • PERROT A
    • PATTI C
    • GASTAUD L
    • SORASIO R
    • DEBAIGT C
    • SCHIAPPA R
    • CHAMOREY E
    • VIVIANI S
    • and THYSS A
  • P085 (0112) Treatment toxicity in elderly Hodgkin lymphoma patients with advanced stage – multicenter retrospective data analysis from the Czech Republic

    • SYKOROVA A.
    • MOCIKOVA H.
    • LUKASOVA M.
    • KOREN J.
    • STEPANKOVA P.
    • PROCHAZKA V.
    • BELADA D.
    • KLASKOVA K.
    • GAHEROVA L.
    • CHROUST K.
    • BURESOVA L.
    • MARKOVA J.
    • on behalf of the Czech Hodgkin Lymphoma Group
  • P086 (0129) Metabolic Tumour Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma

    • Jasmin Mettler
    • Horst Müller
    • Conrad-Amadeus Voltin
    • Christian Baues
    • Bernd Klaeser
    • Alden Moccia
    • Peter Borchmann
    • Andreas Engert
    • Georg Kuhnert
    • Alexander Drzezga
    • Markus Dietlein
    • Carsten Kobe
  • P087 (0135) HODGKIN LYMPHOMA IN HIV-POSITIVE PATIENTS: A SINGLE INSTITUTION RETROSPECTIVE STUDY

    • Ammoni LC
    • Fasola C
    • De Francesco D
    • Micheli V
    • Bombonati G
    • Cattaneo MT
    • De Troia B
    • Ferrario S
    • Filipazzi V
    • Gambaro AR
    • Isabella L
    • Somma L
    • Tosca N
    • and Dalu D
  • P088 (0136) BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH HIGH-RISK ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA (CHL): RESULTS OF PRESPECIFIED SUB-GROUP ANALYSES FROM THE ECHELON-1 STUDY

    • Martin Hutchings
    • John Radford
    • Andrea Gallamini
    • Arpad Illes
    • Anna Sureda
    • Joseph M Connors
    • Alice Sykorova
    • Hirohiko Shibayama
    • Jeremy S Abramson
    • Neil Chua
    • Jonathan W Friedberg
    • Jan Koren
    • Ann Steward LaCasce
    • Lysiane Molina
    • Neil Josephson
    • Eric Song
    • Hina Jolin
    • Rachael Liu
    • Ashish Gautam
    • Stephen Ansell
  • P089 (0137) POPULATION PHARMACOKINETIC (POPPK) MODELING AND EXPOSURE-RESPONSE (ER) ASSESSMENT OF BRENTUXIMAB VEDOTIN EFFICACY AND SAFETY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA (CHL) FROM THE PHASE 3 ECHELON-1 STUDY

    • Ajit Suri
    • Diane R. Mould
    • Gregory Song
    • Graham Collins
    • Chris Endres
    • Jesus Gomez-Navarro
    • Karthik Venkatakrishnan
  • P090 (0141) PET-CT as a prognostic factor in patients with advanced stages in primary diagnosed Hodgkin Lymphoma (HL).

    • Ia. Pastushenko
    • T. Skrypets
    • O.Novosad
    • T. Kadnikova
    • A. Ashykhmin
    • Y. Kmetyuk
    • O. Karpova
    • L. Mykhalska
    • V. Kozlov
    • N. Novikov
    • E. Oliinichenko
    • N. Kostiukova
    • O. Tkachenko
    • O. Karnabeda
    • V. Stratienko
    • I.Kriachok
  • P091 (0159) SERUM sCD30 AND TARC DO NOT CORRELATE WITH PET-BASED RESPONSE ASSESSMENT IN PATIENTS (PTS) WITH STAGE III OR IV CLASSICAL HODGKIN LYMPHOMA (cHL): PHASE 3 ECHELON-1 STUDY OF BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY VS CHEMOTHERAPY ALONE

    • Anna Sureda
    • Joseph M. Connors
    • Anas Younes
    • Andrea Gallamini
    • Stephen M. Ansell
    • Won S. Kim
    • Fiona Miall
    • Ashish Bajel
    • Wanda Knopinska-Posłuszny
    • Carol Anne Ogden
    • Shingo Kuroda
    • Rachael Liu
    • William L. Trepicchio
    • John Radford

Paediatric Hodgkin Lymphoma

Selected for Oral Presentation

  • T022 (0042) Survival by race/ethnicity in pediatric and adolescent patients with Hodgkin lymphoma: A pooled analysis of contemporary Children’s Oncology Group trials

    • Justine M. Kahn
    • Kara M. Kelly
    • Qinglin Pei
    • Debra L. Friedman
    • Frank Keller
    • Rizvan Bush
    • Smita Bhatia
    • Tara O. Henderson
    • Cindy L. Schwartz
    • and Sharon M. Castellino
  • T023 (0106) Safety and early response to the first 2 cycles of Brentuximab Vedotin substituting vincristine in the OEPA / COPDAC regimen for high risk pediatric Hodgkin Lymphoma (HL)

    • Monika L. Metzger
    • Jamie Flerlage
    • Matthew Krasin
    • Jörg M. Bartelt
    • Amy Billett
    • John K. Choi
    • PhD
    • Matthew Ehrhardt
    • Thomas Georgi
    • Dirk Hasenclever
    • Melissa Hudson
    • Sue C. Kaste
    • Regine Kluge
    • Dieter Körholz
    • Lars Kurch
    • Michael Link
    • Dietrich Stoevesandt
    • Christine Mauz-Körholz
  • T024 (0123) The feasibility of deep inspiration breath-hold in children: Results of the TEDDI pilot study

    • Anni Young Lundgaard MD
    • Mirjana Josipovic MSc
    • Laura Rechner MSc
    • Pernille Envold Bidstrup PhD
    • Rune Hansen MSc
    • Sidsel Skov Damkjaer PhD
    • Morten Joergensen MD
    • Akmal Safwat MD
    • PhD
    • Lena Specht MD
    • DMSc
    • Lisa Hjalgrim MD
    • & Maja V. Maraldo MD

Posters

  • P092 (0019) Proteomic identification of plasma biomarkers in children and adolescents with recurrent Hodgkin Lymphoma

    • Ombretta Repetto
    • Lara Mussolin
    • Caterina Elia
    • Lia Martina
    • Maurizio Bianchi
    • Salvatore Buffardi
    • Alesandra Sala
    • Roberta Burnelli
    • Maurizio Mascarin
    • Valli De Re
  • P093 (0028) HOPE to COPE with OPPA/COPP: Experience of GPOH HD-2002 study protocol in Pediatric Hodgkin Lymphoma in a tertiary care hospital in a resource constraint setting

    • Patra PC
    • Phukan A
    • Chakrabarti P
    • Mandal PK
    • Dolai TK
    • De R
    • Baul S
  • P094 (0059) KEYNOTE-667: Phase 2, Open-Label Study of Pembrolizumab in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) With Slow Early Response (SER) to Frontline Chemotherapy

    • Christine Mauz-Körholz
    • Kara Kelly
    • Frank Keller
    • Akash Nahar
    • Arun Balakumaran
    • Lisa Giulino-Roth
  • P095 (0064) Hodgkin’s Lymphoma in adolescents: the Italian Association of Pediatric Hematology and Oncology (AIEOP) experience.

    • R.Burnelli
    • G.Fiumana
    • M.Pillon
    • A.Sala
    • S.Buffardi
    • L.Vinti
    • M.Zecca
    • A.Garaventa
    • R.Rondelli
    • P.Muggeo
    • M.Provenzi
    • P.Farruggia
    • F.Rossi
    • E.Facchini
    • M.Mascarin
    • on behalf of the Italian Association of Pediatric Hematology and Oncology
  • P096 (0085) M1 macrophage polarization prevails in pediatric Hodgkin Lymphoma from Argentina regardless of Epstein Barr virus presence.

    • Jimenez O
    • Barros MH
    • Cohen M
    • De Matteo E
    • Garcia Lombardi M
    • Preciado MV
    • Niedobitek G
    • Chabay P
  • P097 (0105) Implementing an effective pre-accrual quality assurance programme in the UK to ensure accuracy and consistency of radiotherapy contouring for paediatric Hodgkin’s Lymphoma within the EuroNet-PHL-C2 trial (EudraCT 2012-004053-88)

    • P Díez
    • E Gallop-Evans
    • DJ Cutter
    • YC Chang
    • S Sivabalasingham
    • T Ajithkumar
    • DL Hedegaard
    • J Hayward
    • S Daw
  • P098 (0111) Treatment outcomes of Adolescent and young adult (AYA) Hodgkin lymphomas (HL): real world data from a tertiary care cancer centre

    • Manju Sengar
    • Hasmukh Jain
    • Sridhar Epari
    • Siddhartha Laskar
    • Bhausaheb Bagal
    • Tanuja Shet
    • Sumeet Gujral
    • Archi Agrawal
    • Venkatesh Rangarajan
    • Anant Gokarn
    • Nehal Khanna
    • Jayant Sastri Goda
    • Preeti Pawaskar
    • Raajit Chanana
  • P099 (0117) Survival by age in children and adolescents with Hodgkin lymphoma: A pooled analysis of Children’s Oncology Group (COG) trials

    • Justine M. Kahn
    • Kara M. Kelly
    • Qinglin Pei
    • Debra L. Friedman
    • Frank Keller
    • Rizvan Bush
    • Smita Bhatia
    • Tara O. Henderson
    • Cindy L. Schwartz
    • and Sharon M. Castellino
  • P100 (0119) FAMHL: Genetic Study of Families with a High Frequency of classical Hodgkin Lymphoma

    • Jamie E. Flerlage
    • Lynn Goldin
    • PhD
    • Mary L. McMaster
    • Charles Mullighan
    • MBBS
    • MSc
    • Kim Nichols
    • Chimene Kesserwan
    • Kayla Hamilton
    • Jamie Maciaszek
    • Evadnie Rampersaud
    • Gang Wu
    • Max Qian
    • Mariesha Williams
    • Monika L. Metzger
    • Jun J.Yang
  • P101 (0149) PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN PLUS AVD IN PEDIATRIC PATIENTS WITH ADVANCED STAGE NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA

    • Anna Franklin
    • Marco Zecca
    • Flavio Augusto Luisi
    • Gregory Song
    • Ajit Suri
    • E. Jane Leonard
    • Franco Locatelli
  • P102 (0151) Durable remission for two patients with early relapse of Hodgkin lymphoma, treated with Brentuximab Vedotin plus Gemcitabine, without autologous stem cell transplantation: a report from the Children’s Oncology Group

    • Ilia Buhtoiarov
    • Nkechi Mba
    • Crystal De Los Santos
    • Kathleen M McCarten
    • Monika L. Metzger
    • Qinglin Pei
    • PhD
    • Rizvan Bush
    • Kara M Kelly
    • Aron Flagg
    • Rabi Hanna
    • Peter Cole
  • P103 (0152) Stanford V chemotherapy and low dose radiotherapy for children and adolescents with unfavorable and intermediate risk Hodgkin lymphoma: results of a multi-institutional prospective clinical trial

    • Monika L. Metzger
    • Amy L. Billett
    • Alison M. Friedmann
    • Matthew J. Krasin
    • Howard J. Weinstein
    • Eric C. Larsen
    • Karen J. Marcus
    • Chen Li
    • Zhaohua Lu
    • PhD
    • Sarah S. Donaldson
    • Michael P. Link
    • Melissa M. Hudson

Immunotherapy - Clinical

Selected for Oral Presentation

  • T025 (0005) Brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma: follow-up results from the phase 1/2 study

    • Alex F. Herrera
    • Alison J. Moskowitz
    • Nancy L. Bartlett
    • Julie M. Vose
    • Radhakrishnan Ramchandren
    • Tatyana A. Feldman
    • Ann S. LaCasce
    • Stephen M. Ansell
    • Craig H. Moskowitz
    • Keenan Fenton
    • Kazunobu Kato
    • Faith Galderisi
    • Ranjana H. Advani
  • T026 (0025) A Phase II study of SHR-1210, an anti-PD-1 antibody, in Chinese Patients with Relapsed/Refractory classic Hodgkin Lymphoma

    • Jun Zhu
    • Jifeng Feng
    • Xinchuan Chen
    • Tongyu Lin
    • Junning Cao
    • Yanyan Liu
    • Yaozhong Zhao
    • Jie Jin
    • Haiwen Huang
    • Jianda Hu
    • Jun Luo
    • Liling Zhang
    • Hongwei Xue
    • Qingyuan Zhang
    • Yu Yao
  • T027 (0153) Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years

    • Jonathan W. Friedberg
    • Christopher A. Yasenchak
    • Gina D’Amato
    • Beata Holkova
    • Dipti Patel-Donnelly
    • Thomas Anderson
    • Timothy Larson
    • Yinghui Wang
    • Faith Galderisi
    • and Robert Chen
  • T028 (0163) Allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory classical Hodgkin Lymphoma (cHL) patients treated with Nivolumab is associated with an unprecedented low relapse rate

    • Luca Castagna
    • Massimo Magagnoli
    • Rita Mazza
    • Lucia Morello
    • Francesca Ricci
    • Stefania Bramanti
    • Barbara Sarina
    • Jacopo Mariotti
    • Chiara De Philippis
    • Simona Sica
    • Marcello Rodari
    • Martina Sollini
    • Margarita Kirienko
    • Arturo Chiti
    • Armando Santoro
    • Carmelo Carlo-Stella

Selected for Poster Pitch

  • P105 (0032) A phase II study of Pembrolizumab (PEM) followed by AVD for frontline treatment of classical Hodgkin Lymphoma (cHL): interim results

    • P. B. Allen
    • A. M. Evens
    • B. Pro
    • R. Karmali
    • H. Savas
    • G. Dillehay
    • A. Rademaker
    • B. Palmer
    • R. Advani
    • L. I. Gordon
    • J. N. Winter

Posters

  • P104 (0004) Nivolumab in relapsed/refractory classic Hodgkin lymphoma: Experience with ten patients

    • Reyad Dada
    • Yazeed Zabani
  • P106 (0131) Clinical benefit of Nivolumab in Hodgkin Lymphoma but at what price? Example into a Paris University Hospital

    • E. Peyrilles
    • I. Madelaine
    • C. Thieblemont
    • P. Brice
  • P107 (0155) Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma: Updated Efficacy and Safety Analysis of the Phase 2 KEYNOTE-087 Study

    • Pier Luigi Zinzani
    • Robert Chen
    • Philippe Armand
    • Nathalie Johnson
    • Pauline Brice
    • John Radford
    • Vincent Ribrag
    • Daniel Molin
    • Theodoros P. Vassilakopoulos
    • Akihiro Tomita
    • Bastian Von Tresckow
    • Margaret A. Shipp
    • Eunhee Kim
    • Akash Nahar
    • Arun Balakumaran
    • Craig H. Moskowitz

Relapsed/Refractory

Selected for Oral Presentation

  • T029 (0010) Second Autologous Stem Cell Transplantation (ASCT) for Relapsed or Refractory (R/R) Hodgkin Lymphoma (HL) after a Previous Autograft: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.

    • Carmen Martínez
    • Ariane Boumendil
    • Joanna Romejko-Jarosinska
    • Achilles Anagnostopoulos
    • Edgar Faber
    • Xavier Poiré
    • Ibrahim Yakoub-Agha
    • Saad Akhtar
    • Gunhan Gurman
    • Vincenzo Pavone
    • Kazimierz Halaburda
    • Aida Botelho Sousa
    • Gilles Salles
    • Hervé Finel
    • Irma Khvedelidze
    • Silvia Montoto
    • and Anna Sureda
  • T030 (0103) Bendamustine, Gemcitabine, and Dexamethasone (BGD) Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) Is Effective Treatment for Patients with Relapsed/Refractory Hodgkin Lymphoma (rHL) – Results of the Polish Lymphoma Research Group

    • Ewa Paszkiewicz-Kozik
    • Agata Tyczynska
    • Martyna Kotarska
    • Marcin Szymanski
    • Lukasz Targonski
    • Joanna Drozd-Sokolowska
    • Justyna Rybka
    • Elzbieta Wojciechowska-Lampka
    • Joanna Tajer
    • Lidia Poplawska
    • Joanna Romejko-Jarosinska
    • Michal Osowiecki
    • Sebastian Rybski
    • Jan Zaucha
    • Jan Walewski
  • T031 (0110) Five-Year Progression-Free Survival Outcomes From a Pivotal Phase 3 Study of Consolidative Brentuximab Vedotin After Autologous Stem Cell Transplant in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression (AETHERA).

    • Craig H. Moskowitz
    • Jan Walewski
    • Auayporn Nademanee
    • Tamas Masszi
    • Edward Agura
    • Jerzy Holowiecki
    • Muneer H. Abidi
    • Andy I. Chen
    • Patrick Stiff
    • Simonetta Viviani
    • Veronika Bachanova
    • Anna Sureda
    • Teresa McClendon
    • Connie Lee
    • Julie Lisano
    • and John Sweetenham
  • T032 (0130) Relapse after Early-Stage Favorable Hodgkin Lymphoma: Disease Characteristics, Treatment Strategies and their Outcome

    • Paul J. Bröckelmann
    • Horst Müller
    • Teresa Guhl
    • Karolin Behringer
    • Michael Fuchs
    • Bastian von Tresckow
    • Peter Borchmann
    • Andreas Engert

Selected for Poster Pitch

  • P118 (0068) Long Term Safety and Efficacy of Combination of Brentuximab Vedotin and Ipilimumab or Nivolumab in Relapsed / Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412)

    • Catherine S. Diefenbach
    • Fangxin Hong
    • Richard F. Ambinder
    • Jonathon B. Cohen
    • Michael J. Robertson
    • Kevin A. David
    • Ranjana H. Advani
    • Timothy S. Fenske
    • Stefan K. Barta
    • Neil D. Palmisano
    • Jakub Svoboda
    • David S. Morgan
    • Reem Karmali
    • Brad S. Kahl
    • Steven M. Ansell
  • P126 (0121) PD-1 blockade for Hodgkin Lymphoma after Allogeneic Stem Cell Transplantation

    • Julia Meissner
    • Sascha Dietrich
    • Anna Sureda
    • Herve Finel
    • Irma Khvedelidze
    • Luca Castagna
    • Noël Milpied
    • Herve Ghesquieres
    • Ron Ram
    • Ali Bazarbachi
    • Roch Houot
    • Georg Maschmeyer
    • Domenico Russo
    • Jakob Passweg
    • Alexandros Spyridonidis
    • Michael Stadler
    • Stephen Robinson
    • Peter Dreger
    • Silvia Montoto

Posters

  • P067 (0166) VERY LATE RELAPSES (VLRS) IN HODGKIN LYMPHOMA (HL) OCCURING ≥5 YEARS AFTER INITIAL TREATMENT WITH CHEMOTHERAPY ± RADIOTHERAPY (CT±RT): PATTERN OF RISK OVER 35 YEARS AND THE SIGNIFICANCE OF HISTOLOGY

    • Theodoros P. Vassilakopoulos
    • Maria K. Angelopoulou
    • Euridiki Kravariti
    • Maria N. Dimopoulou
    • Marina P. Siakantaris
    • Athanasios Liaskas
    • Gabriela Gainaru
    • Ioannis Assimakopoulos
    • Maria Arapaki
    • Panagiotis Diamantopoulos
    • Ilianna Konstantinou
    • Georgios Boutsikas
    • Kyriaki Petevi
    • Alexandros Kanellopoulos
    • Theofanis Giannikos
    • Chrisovalanti Chatzidimitriou
    • Maria Efstathopoulou
    • Maria Dimou
    • Maria Moschogiannis
    • Xanthi Giakoumis
    • Ilias Pessach
    • Sotirios Sachanas
    • Theo
  • P108 (0001) Allogeneic stem cell transplantation after treatment with checkpoint inhibitors: feasibility and safety in pooled analysis

    • Reyad Dada
    • Binyam Usman
  • P109 (0012) High CR rate in Interim Results of a phase II trial of Nivolumab with or without ICE in relapsed/refractory HL prior to AHCT

    • Robert Chen
    • Joycelynne Palmer
    • Alex Herrera
    • Hun Lee
    • Nicole Tsai
    • Joo Song
    • Kathryn McBride
    • Matthew Mei
    • Jasmin Zain
    • Leslie Popplewell
    • Auayporn Nademanee
    • Steven Rosen
    • Larry Kwak
    • and Stephen Forman
  • P110 (0014) Successful treatment of Hodgkin lymphoma with brentuximab vedotin relapsing after autologous stem cell transplantation

    • Markova J
    • Mocikova H
    • Gaherova L
    • Kozak T. On behalf of the Czech Hodgkin Lymphoma Study Group
  • P111 (0017) Time to relapse in nodular lymphocyte-predominant Hodgkin lymphoma is related to the histopathological pattern at initial diagnosis and relapse

    • Sylvia Hartmann
    • Bianca Schuhmacher
    • Annette Plütschow
    • Julia Bein
    • Anja Mottok
    • Heinz-Wolfram Bernd
    • Alfred C. Feller
    • German Ott
    • Sergio Cogliatti
    • Michael Hummel
    • Falko Fend
    • Leticia Quintanilla-Martinez
    • Harald Stein
    • Wolfram Klapper
    • Peter Möller
    • Ralf Küppers
    • Andreas Rosenwald
    • Andreas Engert
    • Martin-Leo Hansmann
    • Dennis A. Eichenauer
  • P112 (0020) A PHASE II STUDY WITH BENDAMUSTINE PLUS BRENTUXIMAB VEDOTIN IN HODGKIN’S LYMPHOMA IN FIRST SALVAGE SETTING: THE BBV REGIMEN.

    • Alessandro Broccoli
    • Barbara Botto
    • Paolo Corradini
    • Antonello Pinto
    • Alessandro Re
    • Marina Cesaretti
    • Lisa Argnani
    • Umberto Vitolo
    • Pier Luigi Zinzani
  • P113 (0040) Phase I/II study of Brentuximab Vedotin in first refractory/relapsed classical Hodgkin lymphoma patients treated by chemotherapy (ICE) before autologous transplantation.

    • Aspasia Stamatoullas
    • Hervé Ghesquieres
    • Aurore Perrot
    • Philippe Quittet
    • Franck Morschhauser
    • Vincent Ribrag
    • Veronique Edeline
    • and Pauline Brice
    • for the LYSA group
  • P114 (0041) Results of Mini-BEAM as second salvage chemotherapy after DHAP based chemotherapy for relapsed or refractory classical Hodgkin lymphoma

    • Veldman C
    • Nijland M
    • van Meerten T
    • Hoogendoorn M
    • Huls GW
    • Plattel WJ
  • P115 (0048) Brentuximab vedotin (BV) as maintenance or salvage therapy after ASCT for relapsed/refractory (R/R) HL

    • Kameliya Milcheva
    • Yavor Petrov
    • Emilia Naseva
    • Penka Ganeva
    • Kalina Ignatova
    • Georgi Aranaudov and Branimir Spasov
  • P116 (0054) EARLY TRANSPLANT RELATED COMPLICATIONS IN HODGKIN LYMPHOMA PATIENTS RECEIVING PD-1 INHIBITORS BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION

    • Chiara de Philippis
    • Jacopo Mariotti
    • Stefania Bramanti
    • Barbara Sarina
    • Massimo Magagnoli
    • Lucia Morello
    • Armando Santoro
    • Carmelo Carlo-Stella and Luca Castagna.
  • P117 (0063) BENDAMUSTINE IN HEAVILY PRE-TREATED HODGKIN LYMPHOMA PATIENTS

    • Pavlov V.V.
    • Falaleeva N.A.
    • Bogatyreva T.I.
    • Shklyaev S.S.
    • Terekhova A.Yu.
    • Volodina O.M.
  • P119 (0078) Real life data of brentuximab vedotin use in relapsed/refractory HL in Sweden

    • Christine Jansson
    • Ingemar Lagerlöf
    • Johan Linderoth
    • Ann-Sofie Johansson
    • Fredrik Ellin
    • Marzia Palma
    • Urban Jerlström
    • Karin E. Smedby
    • Daniel Molin
  • P120 (0086) Outcomes and Toxicities after Brentuximab vedotin (BV) Maintenance in Relapsed/Refractory Hodgkin Lymphoma Patient Exposed to BV prior to Autologous Hematopoietic Stem Cell Transplant

    • Gunjan L. Shah MD MS
    • Alison J. Moskowitz MD
    • Sridevi Rajvee MBBS
    • Susan J. McCall MSN ANP-BC
    • Molly A. Maloy MS
    • Craig Sauter MD
    • Sergio A. Giralt MD
    • Matthew J. Matasar MD MS
    • Craig H. Moskowitz MD
  • P121 (0089) Sequential time-intensified brentuximab vedotin (BV) followed by gemcitabine, vinorelbine and pegylated liposomal doxorubicine (GVD) as a bridge to autologous transplantation in DHAP resistant relapsed or refractory CD30+ lymphoma

    • Skirmante Cernauskiene
    • Ruta Semaskeviciene
    • Orinta Mickeviciute
    • Laimonas Griskevicius
  • P122 (0090) BRENTUXIMAB VEDOTIN PRIOR TO ALLOGENEIC TRANSPLANTATION IN HODGKIN’S LYMPHOMAS REDUCES CHRONIC GVHD WITHOUT WORSENING THE OUTCOME

    • Francesco Gaudio
    • Patrizio Mazza
    • Angelo Michele Carella
    • Anna Mele
    • Giulia Palazzo
    • Giovanni Pisapia
    • Paola Carluccio
    • Domenico Pastore
    • Nicola Cascavilla
    • Giorgina Specchia
    • Vincenzo Pavone
  • P123 (0107) Next generation sequencing-based clonality assessment of immunoglobulin gene rearrangements distinguishes relapse from second primary Hodgkin lymphoma

    • Diede van Bladel
    • MSc
    • Michiel van den Brand
    • MD PhD
    • Jos Rijntjes
    • BSc
    • Arjen Brinkman
    • PhD
    • Tomas Reigl
    • Nikos Darzentas
    • Corine Hess
    • Konnie Hebeda
    • Han van Krieken
    • Patricia Groenen
    • Blanca Scheijen
  • P124 (0115) RETROSPECTIVE REAL-LIFE STUDY OF THE BEGEV (BENDAMUSTINE, GEMCITABINE, VINORELBINE) REGIMEN IN HEAVILY PRETREATED, RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS

    • Antonio Russo
    • Alessandro Pulsoni
    • Francesca Ricci
    • Rita Mazza
    • Massimo Magagnoli
    • Lucia Morello
    • Marcello Rodari
    • Alessandra Serrao
    • Giorgia Annechini
    • Andrea Nervini
    • Laura Giordano
    • Luca Castagna
    • Arturo Chiti
    • Armando Santoro
    • Carmelo Carlo-Stella
  • P125 (0116) Nivolumab Re-Treatment in Patients With Relapsed/Refractory Hodgkin Lymphoma

    • Stephen M. Ansell
    • Philippe Armand
    • John M. Timmerman
    • Margaret A. Shipp
    • Ulrich Jäger
    • Wolfgang Willenbacher
    • Rao Saleem
    • Julia He
    • Mariana Sacchi
    • Anne Sumbul
    • Alexander M. Lesokhin
  • P127 (0126) Autologous (auto-HCT) and Allogeneic Stem Cell Transplantation (allo-HCT) in the Management of Relapsed/Refractory (RR) Hodgkin Lymphoma (HL). A Retrospective Analysis of the Lymphoma Working Party of the EBMT.

    • Anna Sureda
    • Sonja Genadieva-Stavrik
    • Ariane Boumendil
    • Herve Finel
    • Irma Khvedelidze
    • Sascha Dietricht
    • Peter Dreger
    • Olivier Hermine
    • Chara Kyriakou
    • Stephen Robinson
    • Norbert Schmitz
    • Harry Schouten
    • Alina Tanase
    • Silvia Montoto
  • P128 (0127) SUCCESFUL SLOW DESENSITIZATION TO BRENTUXIMAB VEDOTIN AFTER ANAPHYLAXIS: 3 CASE REPORTS IN THE BASQUE AUTONOMOUS COMMUNITY

    • Otero Longo Itziar
    • Aranbarri Larrañaga Ane
    • Caminos Altuna Nerea
    • Martinez Molina Sara
    • Joral Badas Alejandro
    • Ondarra Segurola Laida
    • Lombardi Iglesias Clara
    • Diez Angulo Rosa Ana
    • Olabarria Santurtun Iciar
    • Araiz Ramirez Maria
    • Ceberio Echechipia Izaskun
  • P129 (0128) Clinical analysis of relapse patterns in Hodgkin Lymphoma

    • Oertel M
    • Kriz J
    • Kerkhoff A
    • Reusch J
    • Kröger K
    • Elsayad K
    • Haverkamp U
    • Lenz G
    • Eich HT
  • P130 (0132) PRIMARY PROGRESSIVE CLASSICAL HODGKIN LYMPHOMA – A SINGLE CENTRE EXPERIENCE

    • C. Afonso
    • A. Roque
    • D. Neves
    • A. Pinto
    • D. Mota
    • R. Guilherme
    • M. Gomes
    • L. Ribeiro
  • P131 (0133) Pooled results of two annual cohorts from an observational prospective study describing brentuximab vedotin use in routine practice in France for Hodgkin Lymphoma: Interim analysis.

    • Sibon David
    • Quittet Philippe
    • Borel Cécile
    • Stamatoullas Aspasia
    • Franchi-Rezgui Patricia
    • Ghesquières Hervé
    • Dulery Rémy
    • Benbrahim Omar
    • Hammoud Mohammad
    • Filliatre-Clément Lauriane
    • De Guibert Sophie
    • Coulibaly Colombe
    • Casasnovas Olivier
    • Bouabdallah Réda
    • and Brice Pauline
    • for ODICE study group
  • P132 (0138) Patterns and Outcomes with Salvage Treatment for Hodgkin Lymphoma (HL) in the Modern Era: A Real-World Analysis from the Community Oncology Setting in the United States

    • AJ Kumar
    • CR Chao
    • AM Rodday
    • NT Cannizzaro
    • R Rodriguez
    • J Feliciano
    • AM Evens
    • SK Parsons
  • P133 (0148) PROGNOSTIC VALUE OF (18) F-FLUORODEOXYGLUCOSE-POSITRON EMISION TOMOGRAPHY ON SURVIVAL IN HODGKIN LYMPHOMA PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION.

    • Eva Domingo-Domènech
    • Carmen Martínez
    • M. del Pilar Perlaza
    • Montserrat Cortes
    • Gonzalo Gutiérrez
    • Rocio Parody
    • María Suárez-Lledó
    • Francesc Fernández-Avilés
    • Isabel Sanchez-Ortega
    • Montserrat Rovira
    • Xavier Setoain
    • Valentín Ortíz
    • Anna Sureda
  • P134 (0156) Induction therapy with everolimus in combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in patients with relapsed or refractory classical Hodgkin lymphoma: a randomized, placebo-controlled phase I/II trial (HD-R3i)

    • Bastian von Tresckow
    • Andreas Hüttman
    • Vladan Vucinic
    • Horst Müller
    • Annette Pluetschow
    • Andreas Viardot
    • Max S. Topp
    • Carsten Kobe
    • Boris Böll
    • Dennis A. Eichenauer
    • Stephanie Sasse
    • Heinz Haverkamp
    • Michael Fuchs
    • Andreas Engert and Peter Borchmann
  • P135 (0160) Brentuximab-Vedotin + Bendamustine : a highly effective salvage treatment un refractory/relapsed patients with Hodgkin Lymphoma

    • D. Martineau
    • M. Sauvezie
    • L. Oberic
    • A. Mazari
    • A. Banos
    • F. Bijou
    • P. Brice
    • Thyss
    • AC Gac
    • E. Gyan
    • N. Milpied
    • K. Bouabdallah
  • P136 (0161) Long term outcome of patients with relapsed / refractory Hodgkin lymphoma treated at a single institution over 25 years

    • Joanna Romejko-Jarosinska
    • Ewa Paszkiewicz-Kozik
    • Joanna Tajer
    • Elzbieta Wojciechowska-Lampka
    • Martyna Kotarska
    • Anna Borawska
    • Lidia Poplawska
    • Katarzyna Domanska-Czyz
    • Beata Ostrowska
    • Wlodzimirz Osiadacz
    • Michal Osowiecki
    • Anna Dabrowska=Iwanicka
    • Monika Swierkowska
    • Lukasz Targonski
    • Marcin Szymanski
    • Robert Konecki
    • Jan Walewski
  • P137 (0165) TREATMENT STRATEGIES AND PROGNOSTIC FACTORS FOR THE OUTCOME OF VERY LATE RELAPSES (VLRs) OCCURRING ≥5 YEARS AFTER INITIAL TREATMENT WITH CHEMOTHERAPY ± RADIOTHERAPY (CT±RT) IN HODGKIN LYMPHOMA (HL): A JOINT STUDY FROM THE UNIVERSITY OF ATHENS AND ISTITUTO

    • Theodoros P. Vassilakopoulos
    • Athanasios Liaskas
    • Giuliana Rizzuto
    • Maria K. Angelopoulou
    • Maria N. Dimopoulou
    • Alberto Mussetti
    • Marina P. Siakantaris
    • Ioannis Assimakopoulos
    • Maria Arapaki
    • Penelope Korkolopoulou
    • Antonello Cabras
    • George Rassidakis
    • Maria Dimou
    • Eleni Variami
    • Panagiotis Panagiotidis
    • Paolo Corradini
    • Kostas Konstantopoulos
    • Gerassimos A. Pangalis
    • Simonetta Viviani
    • TPV and AL had equal contribution to this work.
  • P138 (0167) Long-term High Dose Chemotherapy Before Hematopoietic Stem Cell Transplantation due to Restricted Access to New Therapies

    • Tito Vanelli
    • Gueverson Rocha
    • Caroline Brum
    • Marcelo Capra
    • Elisa Schneider
    • Tahiane Soares
    • Gustavo Fischer
    • Luis Contin
    • Samira Fiorot Lodi
    • Geovana Botan
    • Laura Fogliato
  • P139 (0169) Brentuximab vedotin alone and in combination with bendamustine as salvage therapy for primary refractory or relapsed Hodgkin lymphoma: multicentre experience of the Polish Lymphoma Research Group

    • Czyz A.
    • Lojko-Dankowska A.
    • Joks M.
    • Komarnicki M.
    • Dlugosz-Danecka M.
    • Jurczak W.
    • Rybka J.
    • Wrobel T.
    • Paszkiewicz E.
    • Walewski J.
    • Hawrylecka D.
    • Drozd-Sokolowska J.
    • Subocz E.
    • Szymanska A.
    • Witkowska M.
    • Smolewski P.
    • Giebel S.
    • Zaucha J.M.

General Information

Conference Secretariat

Gürzenich Cologne Martinstraße 29-37 50677 Cologne During the Conference the Secretariat can be contacted at Phone: +49 (0) 173 939 07 30 Email: info@tca-hanke.de

Opening Hours of the Conference Secretariat

Saturday, 27.10.2018 07:00–18:00 Sunday, 28.10.2018 07:00–19:00 Monday, 29.10.2018 07:00–18:00

Accommodation

If you are still in need of a hotel room, please contact the conference management: Phone: +49 (0) 173 939 07 30 Email: info@tca-hanke.de

Name Badge

Please make sure to always wear your badge at the conference. If you lose your badge, we will have to charge you a replace- ment fee.

Catering

During the breaks, complimentary co ee, fruit and refreshments will be available, and other small snacks can be bought. For participants of the scientific symposia, breakfast and lunch will be provided.

Cloakroom

The cloakroom is located in the basement.

Conference Language

The conference language is English.

Insurence

The meeting organizers cannot accept liability for personal injuries sustained to congress participants or for loss or damage of their personal belongings, neither during nor as a result of the meeting.

Internet

There will be free WIFI at the Gürzenich Conference Center. Further details and access codes will be provided on site. You can also use the two on-site internet terminals for web browsing and web-based email access.

Registration

Pre-registration will close on October 26, 2018. All registrations received on or after October 27 will be considered as on-site registrations and will be charged the on-site fee. Full registration will include access to the scientific sessions and exhibition, a copy of the program, the welcome reception on Saturday (October 27) and all refreshment breaks. You will also receive a name tag; please wear this name tag at all conference events including the scientific symposia. No refunds will be given.

Speakers Ready Room

The Speakers Ready Room is located next to the registration desk on the ground floor of the Gürzenich Conference Center. Speakers are requested to hand in their PowerPoint presentations in 16:9 format saved on a stick at least 3 hours before their session or the day before if the session starts early in the morning. We can only accept Windows PowerPoint files for upload to the conference system. It is not permitted to use your own laptops or other devices for uploading the files.

Non-Smoking

Please note that there will be a strict non-smoking policy at all conference facilities.

Welcome Reception

On Saturday evening, the conference will be opened officially. After the Opening Ceremony, all participants are warmly invited to join us at our Get Together event at the Gürzenich Conference Center. This event is a great opportunity to meet and chat with many colleagues involved in Hodgkin Lymphoma research and treatment. Drinks and snacks will be provided.

Acknowledgements

We wish to express our appreciation and gratitude to our partners.

Academic Sponsors

Academic Partners

Conferences

Legal Info

International Symposium on Hodgkin Lymphoma

Prof. Dr. Andreas Engert German Hodgkin Study Group (GHSG) Gleueler Str. 269-273 50935 Köln Phone: +49 (0)221-478 5933 Fax: +49 (0)221-478 3778

Responsible for Content Provided

In accordance with the German Act for Telemedia Services (TMG), § 55 Abs. 2 RStV (section 55, subsection 2 broadcast services state treaty): Prof. Dr. Andreas Engert

Obligatory Information

Legal Entitiy: The University Hospital of Cologne is a Public Law Institution. Legal Representation: The University Hospital of Cologne is represented by the Board of Directors, in turn represented by: Prof. Dr. Edgar Schömig, CEO and medical director Günter Zwilling, Director of finance Kerpener Str. 62 D-50937 Köln

Not Found